Bone Marrow Transplantation - Pipeline Review, H2 2015 Now Available at iData Insights Bone Marrow Transplantation - Pipeline Review, H2 2015 Summary Global Markets Direct s, Bone Marrow Transplantation - Pipeline Review, H2 2015, provides an overview of the Bone Marrow Transplantations therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplantation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bone Marrow Transplantation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bone Marrow Transplantation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplantation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bone Marrow Transplantation pipeline depth and focus of Indication therapeutics - Develop and design inlicensing and out-licensing strategies by identifying prospective partners with the most attractive 1
projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173356/bonemarrow-transplantation-pipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173356/bone-marrow-transplantation-pipeline-review-h2-2015 Table of Contents
Introduction 7 Global Markets Direct Report Coverage 7 Bone Marrow Transplantation Overview 8 Therapeutics Development 9 Pipeline Products for Bone Marrow Transplantation - Overview 9 Pipeline Products for Bone Marrow Transplantation - Comparative Analysis 10 Bone Marrow Transplantation - Therapeutics under Development by Companies 11 Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes 12 Bone Marrow Transplantation - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Bone Marrow Transplantation - Products under Development by Companies 16 Bone Marrow Transplantation - Products under Investigation by Universities/Institutes 17 Bone Marrow Transplantation - Companies Involved in Therapeutics Development 18 Anchor Therapeutics, Inc. 18 Boryung Pharmaceutical Co., Ltd. 19 Cleveland BioLabs, Inc. 20 Compugen Ltd. 21 Mesoblast Limited 22 Pluristem Therapeutics Inc. 23 2
Proteonomix, Inc. 24 Taiga Biotechnologies, Inc. 25 Targazyme, Inc. 26 Bone Marrow Transplantation - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Combination Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 (filgrastim + plerixafor) - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ATI-2341 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 BR-05001 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 CBLB-612 - Drug Profile 42 Product Description 42 Mechanism of Action 42
3
R&D Progress 42 Cell Therapy for Bone Marrow Transplantation - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 CGEN-15001 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 MPC-CBE - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 PLXR-18 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Protein for Bone Marrow Transplantation - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Small Molecules to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 TZ-101 - Drug Profile 53 Product Description 53 4
Mechanism of Action 53 R&D Progress 53 Bone Marrow Transplantation - Recent Pipeline Updates 55 Bone Marrow Transplantation - Dormant Projects 65 Bone Marrow Transplantation - Discontinued Products 66 Bone Marrow Transplantation - Product Development Milestones 67 Featured News & Press Releases 67 Nov 17, 2015: Pluristem to Present New Data on PLX-R18 at American Society of Hematologys Annual Meeting 67 May 06, 2015: Pluristem Granted European Patent for Use of Cells to Help Treat Damaged Bone Marrow 67 Mar 24, 2015: Pluristem Announces Key Strategic Objectives for Development of PLX-R18 in Hematopoietic Indications 68 Mar 03, 2015: Pluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation 68 Dec 04, 2014: Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes 70 Nov 13, 2014: Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials 70 Oct 27, 2014: Case Western Reserve University to Study Pluristems PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases 71 May 07, 2013: Pluristem Develops PLX-RAD Cells For Use In Hematology 72 Sep 05, 2012: Pluristem Therapeutics Announces Successfully Treatment Of Third Critically Ill Patient With PLX Cells Under Compassionate Use 72 May 09, 2012: Pluristem's PLX Cells Saves Life Of Child After Bone Marrow Transplantation Failure 73 Appendix 75 Methodology 75 Coverage 75 Secondary Research 75 Primary Research 75
5
Expert Panel Validation 75 Contact Us 75 Disclaimer 76"
Read More http://www.idatainsights.com/reports-landing-page.php?id=173356/bone-marrowtransplantation-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
6